Clinical Trial Search

Primary: Improvement of the Inflammatory Lesions (Papules, Pustules, Nodules), Erythema, and Telangiectasia of Rosacea as Assessed by the Investigator's Global Assessment (IGA)…

Primary: Success Rate — 40.1; 18.8 Percentage of participants — p=<0.001

Primary: Success Rate — 38.4; 11.6 Percentage of participants — p=<0.001

Primary: Change From Baseline in the Total Number of Papulopustular Lesions at Week 12 — -0.2 papule count — p=0.98

Primary: Co-primary Endpoint: Change From Baseline in Number of Rosacea Inflammatory Lesions — -10.0; -6.7; -9.2 lesions (rosacea inflammatory)

Primary: Degree of Improvement in Erythematotelangiectatic Rosacea and Papulopustular Rosacea — 2.114; 2.088 score on a scale

Primary: Nominal Change From Baseline in Inflammatory Lesion (IL) Count (Sum of Papules and Pustules) at Week 2 (LOCF: Last Observation Carried Forward) — -10.5; -9.4…

Primary: Percentage of Participants Achieving an IGA Score of Clear or Almost Clear From Baseline at Week 12 — 50.1; 25.9 Percentage of Participants

Primary: Percentage of Participants Achieving an IGA Score of Clear or Almost Clear From Baseline at Week 12 — 43.5; 16.1 Percentage of Participants

Primary: Change From Baseline in Papule/Pustule Count at Week 16 — -5.00 papules and pustules — p=0.01

Primary: The Absolute Change From Day 0/Baseline in the Inflammatory Lesion Count at Week 12 — 18.38; 14.53 Lesions — p=<0.0001

Primary: The Absolute Change From Day 0/Baseline in the Inflammatory Lesion Count at Week 12 — 17.56; 15.34 Lesions — p=0.0031

Primary: IGA of Improvement — 3.1; 3.5 units on a scale

Primary: Percent Change in Inflammatory Lesions From Baseline to Week 16 — -83; -73.7 percentage of change

Primary: Clinical Erythema Assessment (CEA) Score At 6-Month Post-Baseline — 1.6; 2.4 score on a scale

Primary: Mean Percent Change From Baseline in the Inflammatory (Papules and Pustules) Lesion Count — 65.47; 67.89; 55.51 percentage of lesion reduction

Primary: Investigator's Global Assessment (IGA) Treatment Success Compared to Placebo. — 74; 22 Participants

Primary: Proportion of Subjects With Composite Success — 60; 58; 23 Participants

Primary: Responder — 16.7 percentage of responders

Primary: Investigator's Global Assessment (IGA) Treatment Success Compared to Placebo. — 79; 25 Participants

Primary: Absolute Change From Baseline in Inflammatory Lesion Count at Week 40 — 23.0; 22.5 Lesions

Primary: Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Success at End of Treatment (LOCF: Last Observation Carried Forward) — 43.4…

Primary: Long Term Safety & Efficacy of CD07805/47 Gel 0.5% in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea. — -1.5; -1.4; -1.5; -1.7 scores on a scale

Primary: Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Success at End of Treatment (LOCF: Last Observation Carried Forward) — 32.1…

Primary: Percent Change (Reduction) of Lesion Count From Day 1 — 61.14; 57.27; 49.43 percentage of lesion reduction

Primary: Total Number of Flushes for Each 2-week Period — 15.3; 16.3 Flushes count — p=0.7420

Primary: Nominal Change From Baseline in Inflammatory Lesion (IL) Count (Sum of Papules and Pustules) Per Participant at End of Study (LOCF: Last Observation Carried Forward)…

Primary: Change From Baseline in Inflammatory Lesion Counts — -4.3; -3.2 inflammatory lesions

Primary: Photoactive Porphyrins Level — 33.0; 24.8; 19.7 Fluorescence intensity unit

Primary: Facial Erythema — 6.6; 6 score on a scale